Related Experiment Video
Updated: Jan 3, 2026
07:12
Time-resolved Förster Resonance Energy Transfer Assays for Measurement of Endogenous Phosphorylated STAT Proteins in Human Cells
Published on: September 9, 2021
4.1K
Targeting the JAK/STAT Pathway in T Cell Lymphoproliferative Disorders
Geoffrey Shouse1, Liana Nikolaenko2
1Department of Hematology/Hematopoietic Cell Transplantation, City of Hope National Medical Center, 1500 E Duarte Road, Duarte, CA, 91010, USA.
Current Hematologic Malignancy Reports
|November 20, 2019
Summary
Targeting the JAK/STAT pathway shows promise for treating T cell lymphoproliferative disorders. Early clinical trials indicate that JAK/STAT inhibition, alone or combined with other therapies, offers potential clinical benefits for these blood cancers.
Area of Science:
- Hematology
- Oncology
- Molecular Biology
Background:
- T cell lymphoproliferative disorders are aggressive blood cancers with limited treatment options.
- The Janus kinase/signal transducer and activator of transcription (JAK/STAT) signaling pathway is frequently dysregulated in these malignancies.
- Targeting aberrant JAK/STAT signaling presents a potential therapeutic strategy.
Purpose of the Study:
- To review current data on JAK/STAT pathway disruptions in T cell malignancies.
- To summarize evidence for exploiting the JAK/STAT pathway with targeted therapies.
Main Methods:
- Review of preclinical studies and early clinical trials.
- Analysis of data on JAK/STAT pathway inhibition in T cell lymphoproliferative disorders.
Main Results:
- Preclinical studies demonstrate the efficacy of JAK/STAT inhibition.
- Early clinical trials show promising results for JAK/STAT-targeted therapies.
- Combination therapies including JAK/STAT inhibitors are under investigation.
Conclusions:
- Targeting the JAK/STAT pathway holds significant clinical potential for T cell lymphoproliferative disorders.
- Ongoing trials are evaluating optimal therapeutic strategies.
- This pathway inhibition may serve as a basis for rational combination therapies.
Keywords:
AITLALCLCTCLJAKNK cell lymphomaPTCLSTATT cell lymphomaT cell lymphoproliferative disordersT-ALLMore Related Videos
Related Concept Videos
01:20The JAK-STAT Signaling Pathway
11.7K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
11.7K
02:57Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K
02:23Abnormal Proliferation
5.0K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.0K
01:31The Intrinsic Apoptotic Pathway
8.1K
Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
8.1K
03:03mTOR Signaling and Cancer Progression
4.6K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
4.6K
01:22T Cell Activation and Clonal Selection
14.5K
T cells are integral to our adaptive immune system, recognizing and effectively responding to foreign antigens. T cell activation and clonal selection are pivotal in orchestrating this immune response. This article elucidates these mechanisms, detailing the roles of cluster of differentiation (CD) markers, major histocompatibility complex (MHC) molecules, costimulatory signals, and the process of clonal selection.
Naive T cells that have not yet encountered an antigen express two primary CD...
Naive T cells that have not yet encountered an antigen express two primary CD...
14.5K